Wecht Jill M, Weir Joseph P, Radulovic Miroslav, Bauman William A
VA RR&D National Center for the Medical Consequences of Spinal Cord Injury, James J. Peters VAMC, Bronx, New York The Medical Service, James J. Peters VAMC, Bronx New York Department of Medicine, The Icahn School of Medicine at Mount Sinai, New York, New York Department of Rehabilitation Medicine, The Icahn School of Medicine at Mount Sinai, New York, New York
Department of Health, Sport and Exercise Sciences, The University of Kansas, Lawrence, Kansas.
Physiol Rep. 2016 Feb;4(3). doi: 10.14814/phy2.12683.
We previously showed that increases in mean arterial pressure (MAP) following administration of midodrine hydrochloride (MH) and nitro-L-arginine methyl ester (L-NAME) resulted in increased mean cerebral blood flow velocity (MFV) during head-up tilt in hypotensive individuals with spinal cord injury (SCI) and question if this same association was evident during cognitive activation. Herein, we report MAP and MFV during two serial subtraction tasks (SSt) given before (predrug) and after (postdrug) administration of MH; (10 mg), L-NAME (1 mg/kg) or no drug (ND) in 15 subjects with SCI compared to nine able-bodied (AB) controls. Three-way factorial analysis of variance (ANOVA) models were used to determine significant main and interaction effects for group (SCI, AB), visit (MH, L-NAME, ND), and time (predrug, postdrug) for MAP and MFV during the two SSt. The three-way interaction was significant for MAP (F = 4.262; P = 0.020); both MH (30 ± 26 mmHg; P < 0.05) and L-NAME (27 ± 22 mmHg; P < 0.01) significantly increased MAP in the SCI group, but not in the AB group. There was a significant visit by time interaction for MFV suggesting an increase from predrug to postdrug following L-NAME (6 ± 8 cm/sec; P < 0.05) and MH (4 ± 7 cm/sec; P < 0.05), regardless of study group, with little change following ND (3 ± 3 cm/sec). The relationship between change in MAP and MFV was significant in the SCI group following administration of MH (r(2) = 0.38; P < 0.05) and L-NAME (r(2) = 0.32; P < 0.05). These antihypotensive agents, at the doses tested, raised MAP, which was associated with an increase MFV during cognitive activation in hypotensive subjects with SCI.
我们之前的研究表明,盐酸米多君(MH)和硝基-L-精氨酸甲酯(L-NAME)给药后平均动脉压(MAP)升高,在脊髓损伤(SCI)的低血压个体进行头高位倾斜时会导致平均脑血流速度(MFV)增加,我们还质疑在认知激活期间这种关联是否同样明显。在此,我们报告了15名SCI受试者与9名健康对照者(AB)在服用MH(10毫克)、L-NAME(1毫克/千克)或无药物(ND)之前(给药前)和之后(给药后)进行的两项连续减法任务(SSt)期间的MAP和MFV。使用三因素方差分析(ANOVA)模型来确定在两项SSt期间,组(SCI、AB)、访视(MH、L-NAME、ND)和时间(给药前、给药后)对MAP和MFV的显著主效应和交互效应。MAP的三因素交互作用显著(F = 4.262;P = 0.020);MH(30±26mmHg;P < 0.05)和L-NAME(27±22mmHg;P < 0.01)均使SCI组的MAP显著升高,但AB组未升高。MFV存在访视与时间的显著交互作用,表明无论研究组如何,L-NAME(6±8厘米/秒;P < 0.05)和MH(4±7厘米/秒;P < 0.05)给药后MFV从给药前到给药后增加,而ND给药后变化很小(3±3厘米/秒)。在SCI组中,服用MH(r² = 0.38;P < 0.05)和L-NAME(r² = 0.32;P < 0.05)后,MAP变化与MFV之间的关系显著。在测试剂量下,这些抗低血压药物升高了MAP,这与SCI低血压受试者在认知激活期间MFV增加有关。